We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNOV icon
326
MediciNova
MNOV
$65M
– –
-474,803
Closed -$1.69M
NBIX icon
327
PUT
Neurocrine Biosciences
NBIX
$17.7B
– –
-241
Closed -$1.36M
NGNE icon
328
Neurogene
NGNE
$696M
– –
-3,016
Closed -$753K
NVO
329
CALL
Novo Nordisk
NVO
$216B
– –
-1,740
Closed -$5.05M
OCUL icon
330
CALL
Ocular Therapeutix
OCUL
$1.86B
– –
-100
Closed -$94K
OCUL icon
331
Ocular Therapeutix
OCUL
$1.86B
– –
-90,000
Closed -$843K
OMER icon
332
Omeros
OMER
$709M
– –
-23,450
Closed -$285K
OPK icon
333
CALL
Opko Health
OPK
$921M
– –
-4,500
Closed -$4.52M
PCRX icon
334
CALL
Pacira BioSciences
PCRX
$1.02B
– –
-553
Closed -$4.25M
PGEN icon
335
CALL
Precigen
PGEN
$1.93B
– –
-328
Closed -$980K
PHG icon
336
CALL
Philips
PHG
$25.4B
– –
-3,317
Closed -$6.04M
PTCT icon
337
PUT
PTC Therapeutics
PTCT
$6.37B
– –
-669
Closed -$2.17M
QURE icon
338
CALL
uniQure
QURE
$2.68B
– –
-950
Closed -$1.57M
QURE icon
339
uniQure
QURE
$2.68B
– –
-13,131
Closed -$217K
QURE icon
340
PUT
uniQure
QURE
$2.68B
– –
-208
Closed -$344K
RMTI icon
341
Rockwell Medical
RMTI
$26.2M
– –
-117
Closed -$132K
RMTI icon
342
PUT
Rockwell Medical
RMTI
$26.2M
– –
-1
Closed -$132K
THC icon
343
CALL
Tenet Healthcare
THC
$20.1B
– –
-1,545
Closed -$4.68M
TPST icon
344
CALL
Tempest Therapeutics
TPST
$14.8M
– –
0
– -$489K
UTHR icon
345
United Therapeutics
UTHR
$26.3B
– –
-34,779
Closed -$4.4M
UTHR icon
346
PUT
United Therapeutics
UTHR
$26.3B
– –
-800
Closed -$12.5M
VTRS icon
347
PUT
Viatris
VTRS
$20.1B
– –
-2,732
Closed -$14.8M
XOMA
348
CALL
DELISTED
Xoma
XOMA
– –
-25
Closed -$67K
NVRO
349
CALL
DELISTED
NEVRO CORP.
NVRO
– –
-301
Closed -$2.03M
NVRO
350
PUT
DELISTED
NEVRO CORP.
NVRO
– –
-798
Closed -$5.39M
12 13
14
15 16

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.